The company focuses on treating inflammatory conditions with its personalised, wearable ultrasound stimulation platform. Credit: Emily frost / Shutterstock.

该公司专注于利用其个性化的可穿戴超声波刺激平台治疗炎症性疾病。 кредит: 艾米丽·弗罗斯特 / Shutterstock。

SecondWave Systems has secured $7m in a Series A funding round to expedite the development of its ultrasound device for inflammatory conditions.

SecondWave Systems 在 A 轮融资中筹集了 700 万美元，以加快其用于炎症性疾病的超声波设备的开发。

The SecondWave MINI device employs “low intensity” focused ultrasound (LiFU) technology for spleen stimulation to treat acute and chronic inflammation disorders.

第二波迷你设备采用“低强度”聚焦超声（LiFU）技术进行脾脏刺激，以治疗急性和慢性炎症疾病。

Go deeper with GlobalData

深入了解更多全球数据

Reports

报告

Intravascular Ultrasound System Market Size (Value, Volume, ASP) by...

血管内超声系统市场规模（价值、数量、平均售价）按...

Reports

报告

Artificial Intelligence in Healthcare: Transcranial Ultrasound

医疗保健中的人工智能：经颅超声波

Data Insights

数据洞察

The gold standard of business intelligence.

商业智能的黄金标准。

Find out more

了解更多

It is currently under clinical trial investigation to manage several inflammatory conditions, including rheumatoid arthritis (RA).

它目前正在进行临床试验，以管理多种炎症状况，包括类风湿关节炎（RA）。

Treo Ventures and a healthcare strategic spearheaded the funding round with contributions from Scientific Health Development, US State Small Business Credit Initiative (SSBCI) funds, and the University of Minnesota’s Discovery Capital.

Treo Ventures和一家医疗战略机构牵头了这轮融资，Scientific Health Development、美国小企业信用倡议（SSBCI）基金以及明尼苏达大学的Discovery Capital也参与了投资。

The investment will bolster the company’s upcoming clinical trial, building on the positive results from its first-in-human trial, which showed a considerable decrease in activity regarding RA.

这项投资将加强该公司即将到来的临床试验，基于其首次人体试验的积极结果，该试验显示 RA 的活动性显著降低。

This latest financing is said to build upon the previous support from US Government partners such as the Advanced Research Projects Agency for Health and the Defense Advanced Research Projects Agency.

据称，这次最新的融资是在美国政府合作伙伴（如卫生高级研究计划局和国防高级研究计划局）之前的支持基础上进行的。

These agencies have backed the research and development of the “noninvasive” wearable therapeutic ultrasound device.

这些机构支持了“非侵入式”可穿戴治疗超声波设备的研发。

SecondWave Systems CEO Anuj Bhardwaj said: “As we work to develop and commercialise the SecondWave MINI as a new class of noninvasive therapy, we are very excited to enter the next phase of development with a strong set of new investor partners.

SecondWave Systems首席执行官Anuj Bhardwaj表示：“在我们努力开发并将SecondWave MINI作为一类新型非侵入性疗法进行商业化的过程中，我们非常高兴能与一批新的强大投资者伙伴一起进入发展的下一阶段。

“Our team at SecondWave is dedicated to improving patient quality of life for millions of Americans who suffer from chronic inflammatory disorders.”

“SecondWave团队致力于改善数百万患有慢性炎症性疾病的美国患者的生活质量。”

SecondWave is focused on treating inflammatory conditions with its personalised, wearable ultrasound stimulation platform.

SecondWave 专注于利用其个性化的可穿戴超声波刺激平台治疗炎症性疾病。

According to the company, its ultrasound-based stimulation has shown potential in modulating or suppressing neural and cellular pathways, offering treatment possibilities for a range of conditions such as inflammation, pain, and other disorders.

据该公司称，其基于超声波的刺激技术已显示出调节或抑制神经和细胞通路的潜力，为炎症、疼痛和其他疾病等一系列病症提供了治疗可能性。

In May 2024, the

2024年5月，

company reported encouraging initial findings

公司报告了令人鼓舞的初步发现

from a pilot study of the wearable therapeutic ultrasound device, targeting chronic and acute inflammatory disorders.

来自针对慢性及急性炎症疾病的可穿戴治疗性超声设备的初步研究。

Sign up for our daily news round-up!

注册获取我们的每日新闻汇总！

Give your business an edge with our leading industry insights.

通过我们领先的行业洞察，为您的企业带来优势。

Sign up

注册

Share

分享

Copy Link

复制链接

Share on X

分享到X

Share on Linkedin

分享到领英

Share on Facebook

分享到 Facebook